Researchers have identified fasting hyperinsulinemia as a primary, yet often overlooked, driver of metabolic dysfunction-associated steatotic liver disease (MASLD). A new review published in Hepatology suggests that elevated insulin levels are not merely a symptom of metabolic syndrome but a direct contributor to liver fibrosis and a potent predictor of major adverse liver and cardiovascular events.
The study, “Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction–associated steatotic liver disease,” led by researchers from the Radcliffe Department of Medicine at the University of Oxford, highlights a dangerous feedback loop between the liver and the pancreas. In patients with MASLD, the liver often fails to clear insulin from the bloodstream effectively. This reduced hepatic insulin clearance leads to chronic hyperinsulinemia, which in turn accelerates the progression of liver fibrosis — the most significant predictor of mortality and severe liver outcomes in metabolic patients.
Historically, clinical focus has remained largely on insulin resistance and blood glucose levels. However, this research argues that the absolute level of fasting insulin provides a unique window into liver health. When the liver’s ability to adjust peripheral insulin levels is compromised, it signals a decline in hepatic function that precedes many traditional diagnostic markers. This metabolic shift marks a transition from simple fat accumulation to more aggressive tissue damage.
Integrating these measures into routine clinical practice could allow for earlier intervention, potentially preventing the progression from simple fatty liver to cirrhosis and cardiovascular disease. Ultimately, prioritizing insulin clearance could redefine the standards of care for millions of patients at risk of chronic liver failure.
“The associated fasting hyperinsulinemia has been independently associated as a predictor of major adverse liver outcomes (MALO) and major adverse cardiovascular events (MACE),” the authors noted. This finding suggests that measuring fasting insulin could serve as a non-invasive “hepatic functional test,” providing clinicians with a low-cost tool to identify high-risk patients before irreversible scarring occurs. By tracking these levels, physicians can better anticipate the risk of cirrhosis or liver failure in patients who might otherwise appear stable.
The implications for patients with type 2 diabetes and metabolic syndrome are significant. Because MASLD is so closely entwined with these conditions, the researchers hypothesize that managing insulin levels directly — rather than just focusing on glucose control — could be a way forward in treating steatotic liver disease. This shift in perspective moves hyperinsulinemia from a “background” metabolic feature to a central target for therapeutic intervention, potentially utilizing newer agents that improve metabolic clearance.
As the global prevalence of metabolic syndrome continues to rise, the need for reliable non-invasive tests (NITs) has never been greater. By adding fasting insulin to the current “armamentarium” of diagnostic tools, healthcare providers may be better equipped to assess the entanglement between liver fibrosis and metabolic dysfunction. This approach offers a more holistic view of the patient’s health, bridging the gap between endocrinology and hepatology. The review concludes that recognizing the role of reduced insulin clearance and subsequent hyperinsulinemia offers a potential path toward more personalized treatment strategies. Integrating these measures into routine clinical practice could allow for earlier intervention, potentially preventing the progression from simple fatty liver to cirrhosis and cardiovascular disease. Ultimately, prioritizing insulin clearance could redefine the standards of care for millions of patients at risk of chronic liver failure.
Loading ...